SIGA Technologies

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SIGA Technologies reports strong revenue diversification and growth opportunities

SIGA Technologies delivered robust financial results in 2022, showcasing revenue diversification and positive cash flows. With a focus on TPOXX and upcoming FDA submissions, the company is poised for growth. Challenges lie in regulatory hurdles and operational complexities, but opportunities abound in US Government procurement and international sales expansion.

SIGA Technologies projects robust 2023 performance with strategic growth initiatives

SIGA Technologies is poised for a successful 2023, driven by strong financial expectations and product delivery targets. The company's focus on innovation, strategic partnerships, and market expansion positions it well for future growth. Challenges in negotiations, clinical trials, and program scalability require careful management to capitalize on emerging opportunities.

SIGA Technologies projects robust growth in 2023 amidst operational challenges

SIGA Technologies is poised for strong financial performance in the second half of 2023, with revenue expectations and operating income growth.
The company's focus on TPOXX as a key treatment for orthopoxviruses and international sales growth positions it well for future success.
While facing challenges in trial data analysis and CEO transition, SIGA has opportunities for market expansion and revenue diversification.

SIGA Technologies reports solid Q3 earnings amidst packaging challenges

SIGA Technologies is navigating packaging delays and inventory build-up while maintaining a strong financial position. Promising programs and trials indicate growth potential, with opportunities for additional orders and upsells in the EU market.

SIGA Technologies excels in Q4 2023 earnings, eyes innovation and growth

SIGA Technologies delivered impressive financial results in Q4 2023, with strong revenue growth and profitability. Despite facing challenges in contract extensions and manufacturing capacity, the company remains focused on innovation and expansion to drive future growth and value creation.

SIGA Technologies excels in Q1 2024, navigates health challenges

SIGA Technologies delivered a strong performance in Q1 2024, marked by revenue growth, operational efficiency, and strategic advancements. While maintaining a solid financial position, the company faces challenges related to public health concerns and regulatory complexities. Leveraging opportunities in product expansion and global partnerships will be key to sustaining growth and market leadership.

SIGA Technologies reports robust Q2 earnings and global expansion plans

SIGA Technologies' Q2 2024 performance reflects strong revenue growth and financial stability.
The company's focus on diversification, international expansion, and innovation positions it for future success.
Challenges in government contract negotiations and regulatory approvals are balanced by growth opportunities and positive outlook.

SIGA Technologies reports robust Q3 earnings and eyes global expansion

SIGA Technologies' Q3 2024 earnings call reflects strong financial performance, strategic partnerships, and a focus on innovation and market expansion.
The company's commitment to product safety, efficacy, and diverse revenue sources positions it well for future growth and sustained profitability.
While facing challenges in regulatory approvals and market competition, SIGA's financial stability, product credibility, and growth opportunities present a positive outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, July  30, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

SIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results

- Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications -

SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications

First Deliveries of Contract Option Exercises Announced in April 2020

SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million

NEW YORK, June  15, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United States Department of Defense (DoD), via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense’s (JPEO-CBRND) Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), has increased research and development funding to approximately $23 million in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration (FDA) for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox. 

SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX® 

- 2,500 Courses Delivered to the Canadian Department of National Defence -

SIGA Technologies Announces First International Delivery of Oral TPOXX®

SIGA Technologies, Inc. (SIGA) CEO Phillip Gomez on Q1 2020 Results - Earnings Call Transcript

Deliveries to Maintain National Security 

SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX®

NEW YORK, April  29, 2020  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Wednesday, May 6, 2020. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.

SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results

- Contract  for up  to  $14.3 million for  15,325 Courses  -

SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence

SIGA Technologies, Inc. (SIGA) CEO Phil Gomez on Q4 2019 Results - Earnings Call Transcript

SIGA to supply TPOXX® To Support Turnstone’s SKV Vaccinia Oncolytic Viral Immunotherapy Program

SIGA Announces Collaboration with Turnstone Biologics

NEW YORK, Dec.  05, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that the CDND intends to purchase up to 15,325 courses of oral TPOXX (tecovirimat) over four years as specified in the ACAN, with an initial purchase of 2,500 courses.  The ACAN is required to remain open for at least 15 days, during which time a potential alternative supplier may submit a competing Statement of Capabilities. The contract would represent the first international order for TPOXX. As SIGA previously announced, the CDND intends to award a contract to support regulatory approval for TPOXX by Heath Canada. The Company is currently targeting a Canadian regulatory filing in the second half of 2020, with regulatory approval anticipated in 2021.

SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®

NEW YORK, Nov.  18, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the Canadian Department of National Defence (CDND) has issued an advanced contract award notice (ACAN), indicating that it intends to award a contract to fund regulatory filing with Health Canada for approval of oral TPOXX®.  The ACAN is required to remain open for approximately 15 days, during which time a potential alternative supplier who meets the ACAN requirements for a smallpox anti-viral therapy that has been approved by national regulatory authority may submit a competing Statement of Capabilities. SIGA is the only company currently able to fulfill this requirement.

SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX®

NEW YORK, Oct.  21, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, Chief Executive Officer, will be a speaker at the Non-Conventional Threats (NCT) Asia Conference in Kuala Lumpur, Malaysia.

SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019

Afya Ltd

BlackLine

Adyen NV

A number of Wall Street's rising hedge fund managers revealed their top stock picks at the annual Sohn San Francisco Investment Conference.

Here are the top stock picks of rising hedge fund stars

NEW YORK, Sept.  26, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference at 3:00 p.m. EDT on Thursday, October 3, 2019 in New York.

SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019

NEW YORK, Sept.  25, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis E. Hruby, the Company’s Chief Scientific Officer, will be a speaker at the 13th Chemical, Biological, Radiological, Nuclear, and Explosive materials (CBRNe) Protection Symposium in Malmö, Sweden.

SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019

NEW YORK, Aug.  28, 2019  (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will participate in an analyst-led fireside chat at the 14th Annual Wells Fargo Securities Healthcare Conference at 3:40 p.m. EDT on Thursday, September 5, 2019 in Boston.

News for SIGA Technologies Stock (SIGA)